Strides Pharma Science Limited Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Strides Pharma Science enters its Q4 earnings print with a focus on scaling its US operations toward a $400 million target by FY2028 while managing a successful pivot in its Ex-US markets. Investors will be looking for updates on the sustainability of recent margin expansion and the progress of its dormant ANDA relaunch pipeline.

Strides Pharma Science Limited Q4 Results Date and Time

The company has scheduled an earnings conference call to discuss Q4 & FY26 audited financial results on May 18, 2026, at 17:00 hrs IST.

The conference call is scheduled for May 18, 2026, at 17:00 hrs IST, featuring MD & Group CEO Badree Komandur and Group CFO Vikesh Kumar.

What to expect from Strides Pharma Science Limited's Q4 FY26 results

In its most recently reported quarter, Strides Pharma posted revenue of Rs. 119.46 Cr, PAT of Rs. 12.82 Cr, and an EBITDA margin of 19.8%. The company is currently executing on its US revenue target of $400 million by FY2028, supported by the identification of 60 dormant ANDAs for potential relaunch. Management has described the recent gross margin expansion to 61.2% in Q3 FY26 as a structural shift rather than a one-time gain, while the Ex-US market has transitioned into an execution phase after contributing 47% of total revenue in the last quarter. The upcoming call will likely address the impact of slower quota allocations for controlled substances and the ongoing recovery timeline for the Access market, which saw a 70% YoY revenue decline in Q3.

Key Things To Watch

Performance vs Guidance Tracking

• US Revenue — $400 million by FY2028 — On track with $70M reported in Q3 FY26
• EBITDA Margin — ~20% in next 3 years — On track with 19.8% achieved in Q3 FY26
• Gross Margin — 58-60% sustainable range — Achieved 61.2% in Q3 FY26

Strategic execution and capex updates

• Sandoz AG SSA portfolio acquisition — USD 12 million consideration — Expected closure Q2 FY27
• Nasal spray pipeline — 1 product filed — Additional filings planned over next 12 months
• Total Capex — INR 300-400 crore for FY26 — H1 FY26 spend reached INR 149 Cr

Operating metric trajectory

• Ex-US market growth — 20% YoY increase in Q3 FY26 — Management indicates build phase is complete
• US market revenue — $70 million in Q3 FY26 — Flat YoY due to quota and seasonal factors
• Access market revenue — $2.6 million in Q3 FY26 — 70% YoY decline due to donor funding shifts

Risks and headwinds to monitor

• Controlled substances — Slower quota allocations — Impacting near-term revenue growth
• Working capital — 124 days cash-to-cash cycle — Increased due to Ex-US business expansion
• Regulatory — Chestnut Ridge facility — Classified as VAL (Voluntary Action Indicated) following February 2026 inspection